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SUMMARY 
 
Objectives: Infections are a common cause of hospitalization in breast cancer patients. We studied the 
risk, clinical characteristics and outcomes of infection-related hospitalizations in this patient 
population. 
Methods: A Swedish registry-based study including 8,338 breast cancer patients diagnosed between 
2001 and 2008, followed prospectively for infection-related hospitalizations until 2010. Standardized 
incidence ratios (SIRs) were calculated using background rates from the general female population. 
Associations with clinical characteristics and mortality were analyzed using flexible parametric 
survival models. 
Results: In total, 720 patients experienced an infection-related hospitalization during a median follow-
up of 4.9 years. Infection rates were highest within the first year of diagnosis (SIR = 5.61, 95% CI; 
4.98-6.32), and site-specific risks were most pronounced for sepsis (SIR = 3.14, 95% CI; 2.66-3.71) 
and skin infections (SIR = 2.80, 95% CI; 2.24-3.50). Older age at diagnosis, comorbidities, markers of 
tumor aggressiveness, chemotherapy and axillary node dissection were independent predictors of 
infectious disease risk. Infection-related hospitalizations were also independently associated with 
overall and breast cancer-specific death.  
Conclusions: A significant number of breast cancer patients are hospitalized with an infection 
following diagnosis, which in turn predicts poor prognosis. The risk profile of infection-related 
hospitalizations is multifactorial, including patient, tumor and treatment-related factors. 
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INTRODUCTION 
 
Breast cancer is the most common malignancy diagnosed in women worldwide and the number of 
prevalent cases is increasing due to the overall rise in breast cancer incidence and improved survival 
rate 
1
. As a result of the increased life expectancy, morbidity after a breast cancer diagnosis has 
become more important from a clinical and public health perspective 
2
. Infections are a common 
complication in breast cancer patients and result from immunosuppression due to treatment or the 
malignancy itself 
3, 4
. Most infections are transient in nature, but their consequences may last longer. 
Severe infections, for instance, have been associated with prolonged hospitalization and treatment 
delay 
5, 6
, and are a major cause of future morbidity and mortality 
3, 7
.  
Despite the considerable impact on patient outcome and health care use, limited data are available on 
the incidence of serious infections in breast cancer patients. Previous studies have primarily focused 
on infection-related hospitalizations during periods of chemotherapy-induced neutropenia 
8, 9
 and data 
beyond the initial treatment period are scarce. Moreover, breast cancer and its treatment may 
predispose to infections at certain organ sites, but no studies to date have reported risk estimates for 
site-specific infections. Also, little is known about the tumor and treatment dependent risk profile and 
the impact of infection-related hospitalizations on mortality. 
In the present study we aimed to assess the risk and prognostic implications of serious infections in 
breast cancer patients. Using registry-based data, we studied the incidence of infection-related 
hospitalizations in breast cancer patients as compared to the general female population, overall and by 
time since diagnosis. We also examined associations with patient, tumor and treatment characteristics 
as well as the impact of infection-related hospitalizations on overall and breast cancer-specific 
survival. 
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PATIENTS AND METHODS 
 
Study population 
The Stockholm Breast Cancer Register (SBCR) is a population-based clinical register recording all 
breast cancer diagnoses occurring in the Swedish counties of Stockholm and Gotland since 1976. The 
register has more than 95% completeness for women aged less than 75 years at diagnosis and contains 
detailed information on tumor characteristics and primary breast cancer treatment, as well as routine 
follow-up information on locoregional recurrence and distant metastasis 
10, 11
. For the present study, 
we identified all women diagnosed with primary invasive breast cancer at age 25-75 years between 
2001 and 2008 (N = 8658). We excluded breast cancer patients with distant metastasis at diagnosis (N 
= 320), leaving a total of 8338 individuals for the analysis. All patients were linked by the unique 
personal identity number to the Swedish Inpatient Register, the Swedish Cancer Register, the Swedish 
Cause of Death Register and the Swedish Emigration Register and follow-up was complete until 
December 31, 2010. The study was approved by the Regional Ethical Review Board in Stockholm, 
Sweden. Background rates from the general female population were available through merges with the 
National Population Register. Since this is a registry-based study, no participant was contacted, and all 
data were anonymized prior to analysis. 
 
Infectious diseases 
Infectious diseases were identified through the Swedish Inpatient Register which has nationwide 
coverage since 1987 and includes all inpatient hospitalizations in Sweden 
12
. Diagnoses were coded 
according to the relevant International Classification of Diseases (ICD) codes and subdivided into site-
specific groups of infections as described elsewhere 
13
  (Supplementary Table S1). For the present 
analysis, we only counted infectious diseases listed as principal diagnosis of hospitalization.  
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Clinical characteristics 
We extracted the following patient, tumor and treatment characteristics from the Stockholm Breast 
Cancer Register: date of diagnosis, tumor size, histological grade, estrogen/progesterone receptor 
(ER/PR) status, axillary lymph node involvement, chemo/endocrine therapy, surgery and axillary 
lymph node dissection. Information on comorbid disease prior to diagnosis was obtained from the 
Swedish Inpatient Register and summarized into the Charlson Comorbidity Index (CCI) score, a 
widely used method for classifying chronic comorbid conditions 
14
.   
 
Follow-up data 
Information on emigrations was collected from the Swedish Emigration Register and date and cause of 
death until 31 December 2010 was extracted from the Swedish Cause of Death Register. The latter 
register covers all residents in Sweden with essentially no missing data, and has been shown to 
correctly classify 98% of all breast cancer deaths 
15
. Follow-up information on distant metastasis, 
locoregional recurrence, and second primary breast cancers was obtained through the Stockholm 
Breast Cancer Register and the Swedish Cancer Register.  
 
Statistical analyses 
We first assessed the rate of infection-related hospitalizations, overall and by infection site. Numbers 
of person-years at risk were calculated from the date of breast cancer diagnosis until the date of 
infectious disease hospitalization, death, emigration, or December 31, 2010 whichever came first. To 
evaluate the impact of the primary tumor/treatment, person-time was ended at recurrent disease 
defined as locoregional recurrence, distant metastasis or a second primary breast cancer. Rates of 
infection-related hospitalizations were modeled using flexible parametric survival models (FPM) 
16
 
with time since diagnosis as underlying time scale. We also compared rates of infectious disease 
hospitalization with those observed in the general population, by calculating age and calendar period 
standardized incidence ratios (SIRs) using background rates from the entire female population resident 
in the Stockholm-Gotland area between 2001 and 2010 (N = 454,704) 
17
. For this analysis, we only 
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included breast cancer patients without a history of infectious disease hospitalization prior to diagnosis 
(N = 7550).  
Next, we studied the risk of infection-related hospitalization by patient, tumor and treatment 
characteristics using FPM which is similar to the Cox proportional hazards model. The main 
advantage of FPM is that non-proportional hazards can easily be fitted, allowing the effect of exposure 
variables to vary over time. In all models, time since diagnosis was the underlying time scale and a 
spline with six knots (five degrees of freedom) was used for the baseline hazard. Proportional hazards 
assumptions were verified using likelihood ratio tests and in case of non-proportionality time-
dependent effects were modelled by adding interaction terms with time using a second spline with four 
knots (three degrees of freedom). We conducted three analyses to assess the impact of clinical 
characteristics: 1). models adjusting for age and calendar year of diagnosis; 2). grouped models 
including respectively all patient, tumor and treatment characteristics with additional adjustment for 
age and calendar year of diagnosis and 3). a multivariable adjusted model including all variables.  
Treatment variables were entered as time-fixed variables at diagnosis in all models, as binary time-
dependent modelling from treatment initiation yielded identical results, due to the short time span 
between diagnosis and therapy start. 
Finally, we studied the impact of infectious disease hospitalization on overall and cause-specific 
mortality using FPM. Infections were entered as binary time-dependent variable, changing from 
unexposed at breast cancer diagnosis to exposed at the date of infection hospitalization. For this 
analysis, we only considered infection-related hospitalizations occurring prior to disease recurrence, as 
defined above. To examine the impact of infection site, we also modelled the effect for each site 
separately. All models were adjusted for patient, tumor and treatment characteristics to assess the 
independent prognostic effect of infection-related hospitalizations. Statistical analyses were carried out 
using SAS version 9.2 and STATA version 12.0. 
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RESULTS 
 
Descriptive characteristics of the breast cancer cohort are summarized in Table 1. Mean age at 
diagnosis was 57.4 years and the median length of follow-up was 4.9 years. In total, 720 patients 
experienced an infection-related hospitalization following diagnosis. When comparing rates of site-
specific infections, respiratory infections and sepsis were most frequently reported. The largest group 
of other infections was unspecified and not classifiable according to organ site (Supplementary Table 
S2). 
Supplementary Table S3 shows the SIRs by time since diagnosis. Overall, breast cancer patients 
showed increased rates of infection-related hospitalizations compared to the general female population 
(SIR = 2.04, 95% CI; 1.89-2.21). Relative risks varied by site, and were most pronounced for sepsis 
(SIR = 3.14, 95% CI; 2.66-3.71) and skin infections (SIR = 2.80, 95% CI; 2.24-3.50) and lowest for 
gastrointestinal infections (SIR = 1.14, 95% CI; 0.92-1.42). For most sites, the risk of infection was 
highest within the first year of diagnosis (SIR = 5.61, 95% CI; 4.98-6.32) with a steep decline 
thereafter, except for urinary tract infections for which no time-dependent risk pattern was observed 
(Supplementary Table 3). Rates for sepsis and skin infections remained increased up to 5 years after 
diagnosis (SIR = 1.95, 95% CI; 1.37-2.78 and 2.37, 95% CI; 1.60-3.50 respectively), while the excess 
rate for all other infections was limited to the first year of diagnosis. 
Figure 1 shows the absolute rates of infection-related hospitalizations by time since diagnosis and 
organ site. The highest infection rate after diagnosis was found for sepsis and respiratory infections, 
with a peak rate of respectively 15 and 22 events per 1000 person-years. Absolute rates were lower for 
skin and gastrointestinal infections, but again with a peak rate in the first year of diagnosis. 
Interestingly, a small second peak in skin infection rate was found 2 years after diagnosis. On the other 
hand, no increased rate was observed for urinary tract infections shortly after diagnosis. 
Table 2 lists the HRs for infection-related hospitalizations by patient, tumor and treatment 
characteristics. Older age at diagnosis and comorbid conditions including a history of infectious 
disease hospitalization were associated with an increased risk of infections. All tumor characteristics 
showed a consistent pattern with the hazard of infection being higher for more aggressive tumors 
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(larger tumors, high-grade tumor and tumors with axillary lymph node involvement), although the 
overall HR was only significant for lymph node status after multivariable adjustment (Table 2). 
Associations with patient and tumor characteristics were similar in analyses excluding chemotherapy-
treated patients (Supplementary Table S4). 
The strongest treatment effect was observed for chemotherapy and axillary node dissection. An 
increased hazard was also found in patients undergoing axillary radiotherapy, but this association did 
not retain significance in multivariable analyses (Table 2). More details on chemotherapy treatment 
were available for 1861 patients, and agent-specific analyses showed a tendency towards a higher risk 
of infection-related hospitalizations among patients receiving taxanes compared to other chemotherapy 
agents (Table 3). 
The proportional hazards assumption was met for all variables except for age, tumor size, histological 
grade, axillary lymph node status, chemotherapy and axillary node dissection (Supplementary Table 
S5). The impact of age varied over time, with older age only having an impact on risk 2 years after 
diagnosis. While not being significant in overall analysis, large and high-grade tumors were 
independently associated with an increased risk of infection-related hospitalizations in the first 6 
months after diagnosis. Time-dependent analyses further showed that the impact of chemotherapy and 
axillary lymph node status and dissection, were only short-term, i.e. not detectable 1 year after 
diagnosis.  
We also assessed the impact of infection-related hospitalizations on mortality, after adjustment for 
patient, tumor and treatment characteristics As shown in Table 4, patients who were hospitalized with 
an infection were at  increased risk of dying from any cause during follow-up (HR = 1.83, 95% CI = 
1.51-2.22). The impact of infection-related hospitalizations was strongest for non-breast cancer 
mortality (HR = 2.85, 95% CI = 2.13-3.80), although risk of breast cancer-specific death was also 
slightly increased in patients experiencing an infection-related hospitalization (HR = 1.37, 95% CI = 
1.05-1.79). Analyses by infection site showed that the adverse impact on breast cancer death was 
mainly driven by respiratory infections (HR = 1.92, 95% CI = 1.26-2.91), and that associations with 
other-cause mortality were strongest for sepsis (HR = 4.51, 95% CI = 2.87-7.09) and respiratory 
infections (HR = 3.61, 95% CI = 2.49-5.24).   
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DISCUSSION 
 
 
Hospitalization due to infection is a common cause of hospitalization in breast cancer patients, but 
estimates of the actual risk and prognostic implications of infection-related hospitalizations are scarce. 
This is the first study reporting risk estimates by time since diagnosis and infection site. In total, 720 
patients experienced an infection-related hospitalization during a median follow-up of 4.9 years. 
Infection rates were highest within the first year of diagnosis, and site-specific risks were most 
pronounced for sepsis and skin infections compared to rates observed in the general population. Older 
age at diagnosis, comorbidities, markers of tumor aggressiveness, chemotherapy and axillary node 
dissection were all independently associated with the risk of infections in multivariable analyses. Our 
data further indicate that infection-related hospitalizations are an independent predictor of overall and 
breast cancer specific survival, associations that are mainly driven by respiratory infections and sepsis. 
 
The infectious disease pattern with high relative risks of sepsis and skin infections is in accordance 
with complications that are commonly seen in breast cancer patients: neutropenia and lymphedema 
18
. 
Chemotherapy-induced neutropenia is a major risk factor for sepsis 
19
 and lymphedema is one of the 
strongest risk factors for skin infections 
20
. Previous studies have shown that the risk of lymphedema 
remains elevated several years after the breast cancer diagnosis 
18, 21
, which is in line with the long-
term risk of skin infections found in the present study. The main driver of the long-term sepsis risk is 
not fully understood, but possible explanations include a suppressed immune system that is further 
weakened by other breast cancer comorbidities and the use of antibiotics for previous infectious events 
not requiring hospitalization. For all other infections, excess rates were limited to the first year of 
diagnosis, except for urinary tract infections for which no time-dependent risk pattern was observed.  
 
The risk of infections after a cancer diagnosis is determined by treatment-related adverse effects, 
underlying immune deficiencies and associated comorbidities 
3
. Since more than one predisposing 
factor may exist in a patient, their cumulative burden may better reflect the actual risk of infections. In 
10 
 
the present study, chemotherapy increased the risk of infection-related hospitalization within the first 
year of diagnosis, i.e. the period of active treatment. Chemotherapy can predispose to infections in 
various ways, namely by direct damage to anatomical barriers (i.e. ulceration of gastrointestinal tract) 
bone marrow suppression and neutropenia, but also indirectly through the use of central venous 
catheters (CVCs) 
3
. When comparing different chemotherapy agents, a tendency was observed towards 
a higher risk of infection-related hospitalizations in patients receiving taxanes. This finding, while 
observational in nature, corresponds with clinical trial data showing a higher incidence of neutropenic 
events with taxane-based regimens compared to other chemotherapy agents 
22
. We also found a short-
term increased risk of infections in patient undergoing axillary node dissection, irrespective of the 
number of nodes dissected. Apart from treatment-specific factors, the tumor itself may also contribute 
to infectious disease susceptibility. Although breast cancers, in contrast to hematological cancers, are 
not inherently linked to an immune deficit, several lines of evidence support a role for 
immunosuppression in tumor initiation and progression.
23-26
 Metastatic processes may also 
compromise the immune system through invasion and mechanical obstruction 
3
, and this could explain 
the observed increased risk of infections in node-positive patients, an association that has been 
reported previously 
8
. Short-term associations with tumor-specific factors may, however, also reflect 
postsurgical complications, which are more common with extensive surgery of large tumors 
3
. Besides 
treatment and tumor related factors, our study shows that a patient’s health status, in terms of age and 
comorbid conditions, is another predisposing factor. Likewise, a previous infectious episode could 
lead to infection reactivation, especially in patients undergoing immunosuppressive therapy 
3
. Thus, 
the underlying mechanisms of infection-related hospitalizations in breast cancer patients are complex 
and multifactorial. 
 
 
We also observed an independent effect of infection-related hospitalizations on overall and breast 
cancer specific survival, associations that were mainly driven by respiratory infections and sepsis. 
There are several explanations for the worsened outcome with infection-related hospitalizations in 
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breast cancer patients. First of all, as a marker of immunosuppression, infections may provide 
additional information that is not captured by traditional prognosticators. Several studies have shown 
that immune parameters have added prognostic value in breast cancer patients in terms of future 
relapses and overall survival.
26, 29, 30
  Second, infection-related hospitalizations may influence 
prognosis through a delay or discontinuation of breast cancer treatment. According to several reports, 
neutropenia and infections, especially those involving the respiratory system, are strong independent 
predictors of chemotherapy interruption 
6, 31
, which in turn impacts disease control. However, the 
observed association between respiratory infections and breast cancer death can also be interpreted as 
early symptom of lung metastases. Since the impact of infection-related hospitalizations on breast 
cancer death was observed for respiratory infections solely, this is also a plausible explanation for this 
specific outcome.  
 
Strengths of our study are the population-based design and linkage to register-based data which 
minimizes loss-to follow-up. Other strengths are the large breast cancer cohort with long-term follow-
up and detailed information on patient, tumor and treatment characteristics. By use of flexible 
parametric models, we were able to investigate time-dependent patterns in infectious disease 
hospitalization and its underlying risk factors. Our study also had limitations. Compared to the general 
population, breast cancer patients may experience a lower threshold for infectious disease 
hospitalization. Referral bias could have resulted in inflated SIRs close to diagnosis, but long-term risk 
estimates are less subject to this type of bias. Another limitation is the potential misclassification of 
the outcome. A recent evaluation of the Swedish Inpatient Register indicates high coverage and 
validity for most hospital diagnoses 
12
, but infectious diseases have not been extensively validated in 
this particular setting. However, previous studies show that inpatient diagnoses are suitable for 
monitoring overall and site-specific infections 
34, 35
. We further tried to minimize the impact of 
potential misclassification by analyzing main diagnoses only. Also, we were unable to study risk 
factors per organ site, due to the limited number of incident events per site-specific infection. Finally, 
we could not investigate the impact of immunomodulatory therapies such as Traztuzumab for human 
12 
 
epidermal growth factor receptor 2 (HER2) positive cancers, as this therapy was not routinely 
prescribed during the study period.  
 
From a clinical perspective, the adverse effect of treatment including chemotherapy needs to be 
balanced against the survival benefit, with recent trial data showing a ~30% reduction in 10-year 
mortality with even moderate chemotherapy regimens 
36
. Moreover, short-term prevention of 
infection-related hospitalizations is challenging in an immunocomprised host, although several 
strategies have been proposed for infectious disease prevention in chemotherapy-treated patients 
including immunizations and simple hygiene measures 
37, 38
. Apart from chemotherapy, we identified 
several patient, tumor and treatment-related risk factors, and this information may aid in the 
development of tailored, preventive strategies. Since more patients survive breast cancer today, the 
number of prevalent cases with infectious complications will increase. Given the impact of infection-
related hospitalizations on morbidity, mortality, and health care associated costs, more efforts are 
needed to reduce the burden of this complication. 
 
Collectively, our study shows that a significant number of breast cancer patients are hospitalized with 
an infection following diagnosis, which in turn predicts poor prognosis. The excess rate of infection-
related hospitalization is highest within the first year of diagnosis, with site-specific risks being most 
pronounced for sepsis and skin infections. We further demonstrate that the risk profile for  infection-
related hospitalizations is multifactorial, with patient, tumor and treatment characteristics contributing 
to risk in a time-dependent manner. In light of the growing number of prevalent breast cancer cases, 
this complication deserves more clinical awareness and investigation.  
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FIGURE LEGENDS 
 
Figure 1. Rates of infection-related hospitalizations by time since diagnosis and organ site. 
Abbreviations: CI = confidence interval; py’s = person-years.  Estimated rates of infection-
related hospitalization per site, as obtained from flexible parametric survival models with time 
since diagnosis as underlying time scale.  
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Table 1. Descriptive characteristics of the study population. 
 
 Stockholm breast cancer cohort 
 (N = 8,338) 
Cohort period 2001/2008-2010 
Age at diagnosis (years)  
  Mean (SD) 57.4 (10.2) 
  Min – Max 25-75 
Duration of follow-up (years)  
  Median (IQR) 4.9 (4.1) 
Total no. of person years at risk 42,576 
Infection rate (per 1000 person years) 16.9 
Age at infection diagnosis 
  Mean (SD) 
 
60.7 (11.5) 
  
No. of infection diagnoses,  N   
 Any infection a 720 
 Respiratory infections 237 
 Sepsis 161 
 Skin infections 83 
 Gastrointestinal infections 104 
 Urinary tract infections 82 
 Other infections 145 
 
Abbreviations: SD = standard deviation; IQR = interquartile range. The study population comprises all women diagnosed with primary 
invasive non-metastatic breast cancer at age 25-75 years in the Stockholm-Gotland region between 2001 and 2008. a Total no. of infection 
diagnoses is smaller than the sum of site-specific infections due to co-occurrence of infections within the same patient.   
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Table 2. Association of patient, tumor and treatment characteristics with risk of infection-related 
hospitalization in breast cancer patients. 
 
   HR (95% CI) a  
 N total / cases Model 1 Model 2 Model 3 
Patient characteristics      
Age at diagnosis c     
  < 55 years 3063 / 238 REF (1.00) REF (1.00) REF (1.00) 
 55-64 years 3033 / 256 1.05 (0.88-1.26) 0.99 (0.83-1.18) 1.12 (0.93-1.34) 
 ≥ 65 years 2242 / 226 1.33 (1.11-1.59) 1.15 (0.96-1.39) 1.34 (1.10-1.64) 
Charlson comorbidity index score     
  0 7385 / 564 REF (1.00) REF (1.00) REF (1.00) 
  1 514 / 83 2.20 (1.74-2.78) 2.03 (1.61-2.58) 1.97 (1.55-2.50) 
  ≥ 2 439 / 73 2.43 (1.89-3.11) 2.27 (1.77-2.92) 2.17 (1.63-2.62) 
Infectious disease history     
  No 7550 / 607 REF (1.00) REF (1.00) REF (1.00) 
  Yes 788 / 113 1.86 (1.52-2.27) 1.62 (1.32-1.99) 1.62 (1.32-1.99) 
Tumor characteristics      
Size in mm c     
  <10 2086 / 134 REF (1.00) REF (1.00) REF (1.00) 
  10-20 3555 / 297 1.37 (1.11-1.68) 1.14 (0.96-1.37) 1.22 (0.98-1.52) 
  >20 2438 / 259 1.89 (1.53-2.33) 1.42 (1.18-1.70) 1.28 (1.00-1.62) 
Histological grade (Elston) c     
  Low 963 / 53 REF (1.00) REF (1.00) REF (1.00) 
  Moderate 2557 / 181 1.30 (0.96-1.77) 1.34 (1.08-1.66) 1.04 (0.76-1.41) 
  High 1539 / 145 1.92 (1.40-2.64) 1.51 (1.19-1.90) 1.17 (0.83-1.64) 
ER status     
  Positive 6353 / 515 REF (1.00) REF (1.00) REF (1.00) 
  Negative 1376 / 146 1.45 (1.20-1.74) 1.23 (0.97-1.56) 1.36 (0.97-1.89) 
PR status     
  Positive 5176 / 422 REF (1.00) REF (1.00) REF (1.00) 
  Negative 2419 / 229 1.28 (1.09-1.50) 1.06 (0.86-1.30) 1.07 (0.87-1.31) 
No. positive lymph nodes c     
  0 5033 / 345 REF (1.00) REF (1.00) REF (1.00) 
  1-4 2241 / 233 1.64 (1.38-1.93) 1.52 (1.28-1.80) 1.18 (0.96-1.46) 
  ≥ 5 714 / 100 2.58 (2.07-3.23) 2.20 (1.72-2.75) 1.50 (1.10-2.05) 
Treatment characteristics      
Endocrine therapy      
 No 1472 / 139 REF (1.00) REF (1.00) REF (1.00) 
 Yes 6701 / 554 0.79 (0.66-0.95) 0.98 (0.81-1.19) 1.28 (0.92-1.49) 
Chemotherapy c     
  No 5113 / 363 REF (1.00) REF (1.00) REF (1.00) 
  Yes 3060 / 330 1.87 (1.60-2.19) 1.54 (1.29-1.84) 1.34 (1.10-1.65) 
Radiotherapy      
  No 1882 / 176 REF (1.00) REF (1.00) REF (1.00) 
  Yes, local 3960 / 259 0.72 (0.59-0.87) 0.80 (0.60-1.05) 0.78 (0.59-1.03) 
  Yes, (loco) regional 1423 / 175 1.56 (1.26-1.93) 1.28 (1.03-1.60) 1.08 (0.84-1.39) 
  Yes, site not specified 935 / 90 0.92 (0.71-1.20) 0.90 (0.66-1.22) 0.87 (0.64-1.19) 
Surgery     
  Partial mastectomy 5014 / 377 REF (1.00) REF (1.00) REF (1.00) 
  Total mastectomy 3205 / 325 1.44 (1.24-1.67) 0.98 (0.78-1.23) 0.90 (0.71-1.13) 
No. of dissected lymph nodes b, c     
  < 5 2741 / 154 REF (1.00) REF (1.00) REF (1.00) 
  5-10 2662 / 244 1.61 (1.30-1.98) 1.25 (0.99-1.56) 1.18 (0.93-1.49) 
  >10 3584 / 281  2.02 (1.65-2.47) 1.46 (1.17-1.82) 1.32 (1.04-1.69) 
 
Abbreviations: HR = hazard ratio; CI = confidence interval. a Hazard ratios as estimated from flexible parametric survival models with time 
since diagnosis as underlying time scale. Model 1: adjusted for age and calendar year of diagnosis; Model 2: grouped models including 
respectively all patient, tumor and treatment characteristics with additional adjustment for age and calendar year of diagnosis; Model 3: 
multivariable adjusted including all variables listed in the table and calendar year of diagnosis. Missingness on individual variables < 5%, 
except for histological grade (39.3%, N = 3279), which was included in the Stockholm-Gotland Breast Cancer Register from 2004 onwards 
and ER status (7.3%, N = 609) and PR status (8.9%, N = 743). b No. of dissected lymph nodes refers to the total number of lymph nodes 
dissected at sentinel node procedure and axillary surgery. c The proportional hazards assumption was not met for age at diagnosis, tumor size, 
histological grade, no. of positive lymph nodes,  chemotherapy and no. of dissected lymph nodes. 
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Table 3. Chemotherapy and risk of infection-related hospitalizations in breast cancer patients, analysis 
by chemotherapy agent. 
 
  HR (95% CI) a   
 N total/cases Model 1 Model 2 Model 3 
Chemotherapy     
  No 5113/363 REF (1.00) REF (1.00) REF (1.00) 
  Yes, anthracyclines  1543/170 1.94 (1.60-2.34) 1.59 (1.29-1.95) 1.39 (1.11-1.74) 
  Yes, taxanes 215/30 3.26 (2.22-4.79) 2.32 (1.55-3.47) 1.96 (1.29-2.98) 
  Yes, CMF 103/14 1.98 (1.15-3.39) 1.74 (1.01-3.00) 1.34 (0.77-2.34) 
  Yes, type unknown 1199/116 1.61 (1.30-2.00) 1.37 (1.09-1.74) 1.22 (0.95-1.58) 
 
Abbreviations: HR = hazard ratio; CI = confidence interval; CMF = cyclophosphamide, methotrexate and fluorouracil based chemotherapy. 
 a Hazard ratios as estimated from flexible parametric survival models with time since diagnosis as underlying time scale. Model 1: adjusted 
for age and calendar year of diagnosis; Model 2: grouped models including respectively all patient, tumor and treatment characteristics with 
additional adjustment for age and calendar year of diagnosis; Model 3: multivariable adjusted including all variables listed in the table and 
calendar year of diagnosis. 
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Table 4. Infection-related hospitalizations and future risk of breast cancer death, distant metastasis and 
locoregional recurrence, overall and by infection site. 
 
 HR (95% CI) a 
 Overall death 
(N = 926) 
Breast cancer death 
(N = 589) 
Other causes of death 
(N = 337) 
Infection-related hospitalization    
  Any infection 1,83 (1,51-2,22) 1,37 (1,05-1,79) 2,85 (2,13-3,80) 
  Respiratory infections 2.58 (1.96-3.40) 1.92 (1.26-2.91) 3.61 (2.49-5.24) 
  Sepsis 1.99 (1.45-2.73) 1.28 (0.82-2.00) 4.51 (2.87-7.09) 
  Skin infections 1.66 (0.91-3.03) 1.30 (0.58-2.93) 2.58 (1.05-6.35) 
  Gastrointestinal infections 1.29 (0.73-2.29) 1.00 (0.45-2.26) 1.51 (0.66-3.45) 
  Urinary tract infections 1.19 (0.69-2.06) 0.88 (0.33-2.39) 1.36 (0.68-2.73) 
  Other infection 1.88 (1.26-2.81) 1.46 (0.84-2.54) 2.77 (1.53-4.99) 
 
Abbreviations: HR = hazard ratio; CI = confidence interval. a Hazard ratios are derived from flexible parametric survival models with 
infection-related hospitalization as time-varying exposure and time since diagnosis as underlying time scale. All hazard ratios are adjusted 
for patient (age at diagnosis, CCI, infectious disease history), tumor (size, grade, ER status, PR status, no. of positive lymph nodes) and 
treatment-related factors (endocrine therapy, chemotherapy, radiotherapy, surgery and no. of dissected lymph nodes) and calendar year of 
diagnosis.  
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Figure 1. 
